Search results for "EV1"

showing 10 items of 134 documents

Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis

2017

Background Interstitial lung disease (ILD) complicates the course of systemic sclerosis (SSc), representing the main cause of death in these patients. The identification of parameters that can predict the early onset and progression of ILD in SSc represents an unmet need in clinical practice. The study was designed to explore whether the surfactant proteins (SP) A and D may be used as noninvasive tools for the early identification of ILD in SSc. Alveolar exhaled nitric oxide (NO) was investigated as a surrogate marker of distal inflammation. Methods Unselected consecutive subjects newly diagnosed with scleroderma and subjects free of respiratory and systemic diseases were recruited. All pat…

AdultMalemedicine.medical_specialtyBreath TestSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologySclerodermaScleroderma03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineDLCOInternal medicineMedicineHumansRespiratory systemLungScleroderma Systemicbusiness.industryPulmonary surfactant-associated proteinMedicine (all)SystemicInterstitial lung diseaseSurfactant protein DNitric oxideGeneral MedicineBiomarkerrespiratory systemmedicine.diseasePulmonary Surfactant-Associated Protein Dmedicine.anatomical_structure030228 respiratory systemBreath Tests030220 oncology & carcinogenesisLung diseaseExhaled nitric oxideFemalebusinessInterstitialLung Diseases InterstitialBiomarkersHuman
researchProduct

Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series.

2012

To assess clinical features and general health status of adult patients with mucopolysaccharidosis (MPS) VI. This report includes the clinical history of patients older than 18 years with slowly progressing MPS VI and the retrospective analysis of the outcomes of available data collected between September 2003 and October 2008 at the Center of Pediatric and Adolescent Medicine, University Medical Center, Johannes Gutenberg-University of Mainz, Germany. Variables included were urinary glycosaminoglycan (uGAG) level, mutation analysis, body height, forced vital capacity (FVC), 6-minute walk test, echocardiographic findings, the need for craniocervical decompression surgery, orthopaedic findin…

AdultMalemedicine.medical_specialtyN-Acetylgalactosamine-4-SulfataseMucopolysaccharidosismedicine.medical_treatmentCarpal tunnel surgeryFEV1/FVC ratioAdolescent medicineYoung AdultValve replacementGermanyGeneticsmedicineHumansAge of OnsetCarpal tunnel syndromeGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis VIbusiness.industryMucopolysaccharidosis VIEnzyme replacement therapymedicine.diseaseSurgeryPhenotypeDisease ProgressionFemalebusinessFollow-Up StudiesJournal of inherited metabolic disease
researchProduct

Parathyroid Hormone as a Novel Biomarker for Chronic Obstructive Pulmonary Disease: Korean National Health and Nutrition Examination Survey

2015

Objective To understand and predict chronic obstructive pulmonary disease (COPD), a biomarker that reflects disease severity is needed. Research Design and Methods Data from 10269 adults aged over 40 years of age were retrieved from the Korea National Health and Nutrition Examination Survey (KNHANES), and 1302 patients met the criteria for COPD. The association between values of vitamin D and parathyroid hormone (PTH), and COPD severity including lung function and quality of life, were analyzed. Results In COPD patients, lung function was inversely related to PTH values (P = 0.02 for FVC [% predicted]; P < 0.001 for FEV1 [% predicted]); however, the association of lung function with vitamin…

AdultMalemedicine.medical_specialtyNational Health and Nutrition Examination Surveylcsh:MedicineParathyroid hormonePulmonary function testingPulmonary Disease Chronic ObstructiveFEV1/FVC ratioInternal medicineRepublic of KoreaVitamin D and neurologyHumansMedicineVitamin Dlcsh:ScienceLungAgedCOPDMultidisciplinarybusiness.industrylcsh:RMiddle AgedNutrition Surveysmedicine.diseaseRespiratory Function Testsrespiratory tract diseasesEndocrinologyParathyroid HormoneMultivariate AnalysisQuality of LifeBiomarker (medicine)lcsh:QFemalebusinessBody mass indexBiomarkersResearch ArticlePLOS ONE
researchProduct

Intensity of physical activity and respiratory function in subjects with and without bronchial asthma.

2007

The aim of this study was to assess the intensity of physical activity of asthmatic adults in Finland and the associations between the intensity of physical activity and respiratory function in asthmatic and nonasthmatic persons. The study population (n=8000) was drawn from the population register to represent the Finnish population aged 30 years or over. Adequate information was available from 7193 subjects (89.9% of the sample). Physical activity at work, at leisure and during commuting was recorded with a standard questionnaire. The responses to the questionnaire were expressed as MET values. Asthma was defined on the basis of self-reports of chronic diseases previously diagnosed by a ph…

AdultMalemedicine.medical_specialtyPhysical Therapy Sports Therapy and RehabilitationPhysical exerciseFEV1/FVC ratioMedicineHumansOrthopedics and Sports MedicineRespiratory functionRespiratory systemExerciseAsthmaAgedAged 80 and overbusiness.industryRespirationRespiratory diseaseMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesIntensity (physics)Cross-Sectional StudiesSpirometryPhysical therapyPopulation studyRegression AnalysisbusinessScandinavian journal of medicinescience in sports
researchProduct

Alveolar nitric oxide and asthma control in mild untreated asthma

2012

Background The role of the peripheral airways in asthma is increasingly being recognized as a potential target for the achievement of optimal control of the disease. We postulated that the inflammatory changes of the small airways are implicated in the lack of asthma control in mild asthma. Objective To test this hypothesis, we measured the alveolar fraction of exhaled NO (C alv NO) in patients with mild asthma with different levels of control of symptoms. Methods Seventy-eight patients with asthma (35 men, age, 37 ± 15 years; FEV 1 percentage of predicted, 100% ± 9%) were studied. Asthma control was assessed by using the Asthma Control Test (ACT). Measurements of exhaled NO at multiple con…

AdultMalemedicine.medical_specialtyVital capacityImmunologySettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideGastroenterologyNitric oxideYoung Adultchemistry.chemical_compoundFEV1/FVC ratioAsthma controlInternal medicinemedicineHumansImmunology and AllergyYoung adultAsthmabusiness.industryExhalationmedicine.diseaseAsthmaRespiratory Function Testsrespiratory tract diseaseschemistryExhalationAnesthesiaFemalebusinessAsthma Control TestJournal of Allergy and Clinical Immunology
researchProduct

Nasal IgE in subjects with allergic and non-allergic rhinitis

2020

Abstract Purpose The prevalence of "ocal allergic rhinitis" within individuals suffering from perennial rhinitis remains uncertain, and patients usually are diagnosed with non-allergic rhinitis. The aim of this study was to evaluate the prevalence of a potential "local allergic rhinitis" in subjects suffering from non-allergic rhinitis in a non-selected group of young students. Methods 131 students (age 25.0 ± 5.1 years) with a possible allergic rhinitis and 25 non-allergic controls without rhinitis symptoms (age 22.0 ± 2.0 years) were recruited by public postings. 97 of 131 students with rhinitis were tested positive (≥3 mm) to prick testing with 17 frequent allergens at visit 1. Twenty-fo…

AllergyNon-allergic rhinitismedicine.medical_treatmentImmunoglobulin EAR + HDM allergic rhinitis with house dust mite allergyAllergic rhinitisHDM house dust miteNPT nasal provocation testsAR allergic rhinitis0302 clinical medicineISAAC International Study of Asthma and Allergies in Childhood questionnaireNARES non-allergic rhinitis with eosinophilia-syndromeMedicine and Health SciencesImmunology and Allergy030223 otorhinolaryngologyeducation.field_of_studybiologymedicine.diagnostic_testRadioallergosorbent testsIgE allergen-specific IgENon-allergicD1 Dermatophagoides pteronyssinusPREVALENCED2 Dermatophagoides farinaeLAR local allergic rhinitisPROVOCATION TESTSPulmonary and Respiratory Medicinelcsh:Immunologic diseases. AllergyLOCAL IGEImmunologyPopulationPATHOPHYSIOLOGYNon-allergic-rhinitisLocal allergic rhinitisGCP Good Clinical PracticeDIAGNOSISNasal provocation testArticleSECRETIONS03 medical and health sciencesFEV1/FVC ratiorhinitismedicineddc:610educationHouse dust mitebusiness.industryFEV1 forced expiratory volume in one secondRAST Radioallergosorbent Testbiology.organism_classificationmedicine.disease030228 respiratory systemHouse dust mite allergyPNIF peak nasal inspiratory flowImmunologyFVC forced vital capacitybiology.proteinbusinessSD standard deviationlcsh:RC581-607Local IgESPT skin prick testWorld Allergy Organization Journal
researchProduct

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acet…

2010

Pulmonary function is impaired in untreated mucopolysaccharidosis type VI (MPS VI). Pulmonary function was studied in patients during long-term enzyme replacement therapy (ERT) with recombinant human arylsulfatase B (rhASB; rhN-acetylgalactosamine 4-sulfatase). Pulmonary function tests prior to and for up to 240 weeks of weekly infusions of rhASB at 1 mg/kg were completed in 56 patients during Phase 1/2, Phase 2, Phase 3 and Phase 3 Extension trials of rhASB and the Survey Study. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and, in a subset of patients, maximum voluntary ventilation (MVV), were analyzed as absolute volume in liters. FEV1 and FVC showed little change f…

Arylsulfatase BAdultmedicine.medical_specialtyVital capacityAdolescentMucopolysaccharidoses (MPS)N-Acetylgalactosamine-4-SulfataseMucopolysaccharidosis type VIClinical SciencesUrologyPulmonary function testingPlacebos03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineRare DiseasesDouble-Blind MethodClinical ResearchmedicineGeneticsHumansGenetics(clinical)Longitudinal StudiesChildPreschoolLungGenetics (clinical)Genetics & Heredity0303 health sciencesLungMucopolysaccharidosis VIbusiness.industry030305 genetics & heredityEvaluation of treatments and therapeutic interventionsMucopolysaccharidosis VIEnzyme replacement therapyRecombinant Proteins3. Good healthSurgeryRespiratory Function Testsmedicine.anatomical_structureCross-Sectional StudiesResearch DesignChild Preschool6.1 PharmaceuticalsOriginal Articlebusiness030217 neurology & neurosurgery
researchProduct

Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoG…

2019

This multicenter/multinational, open-label, ascending-dose study (NCT01898364) evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of repeat-dose avalglucosidase alfa (neoGAA), a second-generation, recombinant acid α-glucosidase replacement therapy, in late-onset Pompe disease (LOPD). Patients ≥18 years, alglucosidase alfa naïve (Naïve) or previously receiving alglucosidase alfa for ≥9 months (Switch), with baseline FVC ≥50% predicted and independently ambulatory, received every-other-week avalglucosidase alfa 5, 10, or 20 mg/kg over 24 weeks. 9/10 Naïve and 12/14 Switch patients completed the study. Avalglucosidase alfa was well-tolerated; no deaths…

Avalglucosidase alfa (neoGAA)0301 basic medicineMaleGLUCOSE TETRASACCHARIDELysosomal acid alpha-glucosidase (GAA) deficiencyCHILDRENPulmonary function testingMOTOR FUNCTION0302 clinical medicineMedicineGenetics (clinical)Late-onset Pompe disease (LOPD)Glycogen Storage Disease Type IIAlglucosidase alfaMOUSE MODELEnzyme replacement therapyMiddle AgedTreatment OutcomeNeurologyTolerabilityEnzyme replacement therapySKELETAL-MUSCLEFemaleLife Sciences & BiomedicineMUSCLE TRAINING RMTGlycogen6-MINUTE WALKmedicine.drugAdultmedicine.medical_specialtyClinical NeurologyGLYCOGEN03 medical and health sciencesFEV1/FVC ratioPharmacokineticsInternal medicineHumansEnzyme Replacement TherapyAdverse effectAlglucosidase alfaScience & Technologybusiness.industryNeurosciencesalpha-GlucosidasesADULTSGlycogen storage disease type IISEVERITY030104 developmental biologyPharmacodynamicsPediatrics Perinatology and Child HealthNeurosciences & NeurologyNeurology (clinical)Glucan 14-alpha-Glucosidasebusiness030217 neurology & neurosurgeryNeuromuscular Disorders
researchProduct

GOLD Staging System is Appropriate to Predict Mortality in Older People With Chronic Obstructive Pulmonary Disease

2018

Abstract Introduction In the new GOLD classification the reduction of FEV1, expressed as percentage of predicted value (FEV1PP), is considered an important prognostic factor. However, the use of FEV1PP may introduce bias, especially if based on equations derived from populations different from the one under study. We evaluated how well the GOLD classification stratifies the mortality risk when FEV1PP is based on an equation developed in the same population that gave rise to cases, externally developed equations, or as FEV1 divided by cubed height (FEV1/Ht3). Methods We studied 882 participants aged ≥65 years. Bronchial obstruction was defined using a fixed cut-off of 0.7 for FEV1/FVC. Predi…

BODE indexPulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesFEV1/FVC ratioFEV10302 clinical medicineElderlyInternal medicinemedicine030212 general & internal medicineGOLDeducationStaging systemCOPDeducation.field_of_studybusiness.industryChronic obstructive pulmonary diseaseHazard ratioGeneral Medicinerespiratory systemmedicine.diseaserespiratory tract diseases030228 respiratory systemQuartilebusiness
researchProduct

Iperreattività bronchiale aspecifica in pazienti monosensibili con rinite allergica: variazioni stagionali in rapporto alle IgE sieriche totali ed ag…

2005

Introduction: The significance of the association between allergic rhinitis and abnormal airway responsiveness is unclear. For this reason, we have studied, in patients with seasonal allergic rhinitis, non specific bronchial hyperreactivity, total serum IgE and blood eosinophils, with reference to the responsible allergen, during and out of the pollen season. Materials and methods: Fourty-nine, non-smoking patients, living in Palermo, with clinical diagnosis of allergic rhinitis, skin prick tests and specific serum IgE mono-sensitive to pollen allergens, were enrolled in the study. Twenty patients suffered from seasonal rhinitis to Parietaria pollen, 15 patients to Graminacee pollen and 14 …

Blood eosinophils countNon specific bronchial hyperreactivitySeasonal allergic rhinitiTotal serum IgEPC20-FEV1
researchProduct